Equity Investment Corp increases its stake in Johnson & Johnson (NYSE:JNJ)
Equity Investment Corp increased its stake in Johnson & Johnson (NYSE:JNJ – Get a rating) by 2.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor held 466,704 shares of the company after purchasing an additional 9,445 shares during the quarter. Johnson & Johnson accounts for 2.8% of Equity Investment Corp’s portfolio, making the stock its 14th largest holding. Equity Investment Corp’s holdings in Johnson & Johnson were worth $82,714,000 when it last filed with the SEC.
A number of other institutional investors have also recently changed their holdings in JNJ. Norges Bank purchased a new equity stake in Johnson & Johnson in the fourth quarter valued at approximately $4,172,929,000. BlackRock Inc. increased its holdings in Johnson & Johnson by 2.6% during the fourth quarter. BlackRock Inc. now owns 200,021,352 shares of the company worth $34,217,654,000 after purchasing an additional 4,982,885 shares in the last quarter. GQG Partners LLC increased its stake in Johnson & Johnson by 1,109.4% during the fourth quarter. GQG Partners LLC now owns 3,954,383 shares of the company worth $676,375,000 after purchasing an additional 3,627,424 shares in the last quarter. State Street Corp increased its stake in Johnson & Johnson by 1.8% during the fourth quarter. State Street Corp now owns 144,677,639 shares of the company worth $24,750,004,000 after purchasing an additional 2,492,359 shares in the last quarter. Finally, the Swiss National Bank increased its holdings in Johnson & Johnson by 14.0% during the first quarter. The Swiss National Bank now owns 11,402,516 shares in the company worth $2,020,868,000 after buying an additional 1,396,500 shares in the last quarter. 68.78% of the shares are currently held by hedge funds and other institutional investors.
Insider Trading at Johnson & Johnson
In other news, CAD Robert J. Decker sold 8,462 shares of the company in a trade dated Thursday, May 26. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares of the company, valued at $2,785,140. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available via this link. Separately, Executive Vice President Kathryn E. Wengel sold 40,000 shares in a trade that took place on Friday, June 10. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares of the company, valued at approximately $12,336,803. The sale was disclosed in a filing with the Securities & Exchange Commission, accessible via this link. Additionally, CAO Robert J. Decker sold 8,462 shares in a trade that took place on Thursday, May 26. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following completion of the transaction, the chief accounting officer now directly owns 15,473 shares of the company, valued at $2,785,140. Disclosure of this sale can be found here. Insiders of the company own 0.35% of the shares of the company.
Wall Street analysts predict growth
Several stock analysts have recently released reports on the company. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong buy” rating in a Tuesday, May 17 report. Daiwa Capital Markets began covering Johnson & Johnson in a report on Wednesday June 22. They gave the company an “outperform” rating. SVB Leerink reduced its price target on Johnson & Johnson from $200.00 to $194.00 in a Wednesday, July 20 report. Morgan Stanley raised its price target on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a Friday, July 8 report. Finally, Citigroup reduced its price target on Johnson & Johnson from $205.00 to $201.00 in a Wednesday, July 20 report. Four equity research analysts gave the stock a hold rating, five issued a buy rating and one gave the stock a strong buy rating. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $189.89.
Johnson & Johnson Price Performance
JNJ Stock opened at $169.31 on Monday. The stock has a 50-day moving average price of $173.43 and a 200-day moving average price of $174.57. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt ratio of 0.37. The company has a market capitalization of $445.15 billion, a PE ratio of 24.64, a growth price-earnings ratio of 3.22 and a beta of 0.59.
Johnson & Johnson (NYSE:JNJ – Get a rating) last released its quarterly results on Tuesday, July 19. The company reported earnings per share (EPS) of $2.59 for the quarter, beating analyst consensus estimates of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The company posted revenue of $24.02 billion in the quarter, versus a consensus estimate of $23.85 billion. In the same quarter a year earlier, the company earned $2.48 per share. The company’s quarterly revenue increased 3.0% from the same quarter last year. As a group, research analysts predict Johnson & Johnson will post EPS of 10.05 for the current year.
Johnson & Johnson Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6. Shareholders of record on Tuesday, August 23 will receive a dividend of $1.13. This represents an annualized dividend of $4.52 and a dividend yield of 2.67%. The ex-dividend date is Monday, August 22. Johnson & Johnson’s payout ratio is 65.79%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.
Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.